Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 204-213

  Røge, Rasmus ^a   Møller, Bjarne K ^b   Andersen, Christian R ^a   Correll, Christoph U ^c,d,e,f   Nielsen, Jimmi ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Adverse effects; Agranulocytosis; Clozapine; Cytokines; Immunology; Myocarditis

Indexed keywords

CLOZAPINE; CYTOKINE; PLACEBO;

ADVERSE OUTCOME; AGRANULOCYTOSIS; BLOOD DYSCRASIA; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; FEVER; FLU LIKE SYNDROME; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NONHUMAN; OBESITY; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOKINES; DATABASES, FACTUAL; HUMANS; IMMUNE SYSTEM; SCHIZOPHRENIA;

EID: 84865339859     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.020     Document Type: Review

References (115)

1. Ames D., Wirshing W.C., Baker R.W., Umbricht D.S., Sun A.B., Carter J., Schooler N.R., Kane J.M., Marder S.R. Predictive value of eosinophilia for neutropenia during clozapine treatment. J. Clin. Psychiatry 1996, 57(12):579-581.
2. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., Zou W., Whalen H., Malhotra A.K., Lencz T., Gerson S.L., Kane J.M., Reed C.R. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72(4):458-463.
3. Atkin K., Kendall F., Gould D., Freeman H., Liberman J., O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br. J. Psychiatry 1996, 169(4):483-488.
4. Bailey P. Clozapine treatment, eosinophilia and agranulocytosis. Br. J. Psychiatry 1997, 171:90.
5. Bayard J.M., Descamps O.S., Evrard S., Dumonceau J.M., Servais L., Zingir Z., Adams S., Dassy V., Stillemans E., Seutin A., Titeca P., Titeca J. Case report: acute pancreatitis induced by clozapine. Acta Gastroenterol. Belg. 2005, 68(1):92-94.
6. Bergemann N., Ehrig C., Diebold K., Mundt C., von Einsiedel R. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999, 32(2):78-80.
7. Bergemann N., Abu-Tair F., Aderjan R., Kopitz J. High clozapine concentrations in leukocytes in a patient who developed leukocytopenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(5):1068-1071.
8. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008, 19(1):41-52.
9. Blum A. Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment?. J. Clin. Psychiatry 1990, 51(6):259-260.
10. Bray A., Reid R. Successful clozapine rechallenge after acute myocarditis. Aust. N. Z. J. Psychiatry 2011, 45(1):90.
11. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36(1):71-93.
12. Byrne M., Agerbo E., Bennedsen B., Eaton W.W., Mortensen P.B. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr. Res. 2007, 97(1-3):51-59.
13. Chen D.C., Qi L.Y., Xiu M.H., Cao L.Y., Wang F., Chen S., Wu G.Y., Kosten T.A., Kosten T.R., Zhang X.Y. Elevated serum levels of tumor necrosis factor-α in clozapine-associated obesity in chronic schizophrenia. Schizophr. Res. 2008, 106(2-3):367-368.
14. Corzo D., Yunis J.J., Salazar M., Lieberman J.A., Howard A., Awdeh Z., Alper C.A., Yunis E.J. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995, 86(10):3835-3840.
15. Delieu J.M., Badawoud M., Williams M.A., Horobin R.W., Duguid J.K. Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients. J. Psychopharmacol. 2001, 15(13):191-194.
16. Deliliers G.L., Servida F., Lamorte G., Quirici N., Soligo D. In vitro effect of clozapine on hemopoietic progenitor cells. Haematologica 1998, 83(10):882-889.
17. Dettling M., Schaub R.T., Mueller-Oerlinghausen B., Roots I., Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001, 11:135-141.
18. Dettling M., Cascorbi I., Opgen-Rhein C., Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 2007, 7(5):325-332.
19. Devarajan S., Kutcher S.P., Dursun S.M. Clozapine and sudden death. Lancet 2000, 355(9206):841.
20. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006, 20(6):532-545.
21. Dunk L.R., Annan L.J., Andrews C.D. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br. J. Psychiatry 2006, 188:255-263.
22. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 2006, 163(3):521-528.
23. Elkis H. Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 2007, 30(3):511-533.
24. Essali A., Al-Haj Haasan N., Li C., Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst. Rev. 2009, (1):CD000059. [Jan 21].
25. Flanagan R.J., Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 2008, 23(Suppl. 1):27-41.
26. Gardner I., Zahid N., MacCrimmon D., Uetrecht J.P. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol. Pharmacol. 1998, 53(6):991-998.
27. Garlipp P., Rosenthal O., Haltenhof H., Machleidt W. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. J. Psychopharmacol. 2002, 16(4):399-400.
28. Ghaznavi S., Nakic M., Rao P., Hu J., Brewer J.A., Hannestad J., Bhagwagar Z. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am. J. Psychiatry 2008, 165(7):813-818.
29. Guest I., Sokoluk B., MacCrimmon J., Uetrecht J. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998, 131(1):53-65.
30. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kühn M., Schuld A., Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 1999, 33(5):407-418.
31. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007, 30(1):47-57.
32. Haglund C., Aleskog A., Håkansson L.D., Höglund M., Jacobsson S., Larsson R., Lindhagen E. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol. Lett. 2010, 194(3):102-107.
33. Himmerich H., Schönherr J., Fulda S., Sheldrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. J. Psychiatr. Res. 2011, 45(10):1358-1365.
34. Honigfeld G., Arellano F., Sethi J., Bianchini A., Schein J. Reducing clozapine-related morbidity and mortality: 5years of experience with the Clozaril National Registry. J. Clin. Psychiatry 1998, 59(Suppl. 3):3-7.
35. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43(11):1271-1278.
36. Hummer M., Kurz M., Barnas C., Saria A., Fleischhacker W.W. Clozapine-induced transient white blood count disorders. J. Clin. Psychiatry 1994, 55(10):429-432.
37. Hummer M., Sperner-Unterweger B., Kemmler G., Falk M., Kurz M., Oberbauer H., Fleischhacker W.W. Does eosinophilia predict clozapine induced neutropenia?. Psychopharmacology (Berl) 1996, 124(1-2):201-204.
38. Husain Z., Almeciga I., Delgado J.C., Clavijo O.P., Castro J.E., Belalcazar V., Pinto C., Zuñiga J., Romero V., Yunis E.J. Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol. Appl. Pharmacol. 2006, 214(3):326-334.
39. Igue R., Potvin S., Bah R., Stip E., Bouchard R.H., Lipp O., Gendron A., Kouassi E. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(7):1695-1698.
40. Iverson S., Kautiainen A., Ip J., Uetrecht J.P. Effect of clozapine on neutrophil kinetics in rabbits. Chem. Res. Toxicol. 2010, 23(7):1184-1191.
41. Jeong S.H., Ahn Y.M., Koo Y.J., Kang U.G., Kim Y.S. The characteristics of clozapine-induced fever. Schizophr. Res. 2002, 56(1-2):191-193.
42. Joy C.B., Adams C.E., Lawrie S.M. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2006, 2001(2):CD003082.
43. Juul-Povlsen U., Noring U., Fog R., Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12years. Acta Psychiatr. Scand. 1985, 71(2):176-185.
44. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
45. Kang B.J., Cho M.J., Oh J.T., Lee Y., Chae B.J., Ko J. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?. Hum. Psychopharmacol. 2006, 21(6):387-391.
46. Kilian J.G., Kerr K., Lawrence C., Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999, 354(9193):1841-1845.
47. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., Hinze-Selch D., Kraus T., Dittmann R.W., Pollmächer T. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34(1):118-128.
48. Koller E.A., Cross J.T., Doraiswamy P.M., Malozowski S.N. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003, 23(9):1123-1130.
49. Lahdelma L., Ahokas A., Andersson L.C., Suvisaari J., Hovatta I., Huttunen M.O., Koskimies S. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J. Clin. Psychopharmacol. 2001, 21(1):4-7.
50. Lahdelma L., Oja S., Korhonen M., Andersson L.C. Clozapine is cytotoxic to primary cultures of human bone marrow mesenchymal stromal cells. J. Clin. Psychopharmacol. 2010, 30(4):461-463.
51. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
52. Leykin I., Mayer R., Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997, 37(1):75-86.
53. Lieberman J.A., Safferman A.Z. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr. Q. 1992, 63(1):51-70.
54. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28(5):995-1003.
55. Löffler S., Klimke A., Kronenwett R., Kobbe G., Haas R., Fehsel K. Clozapine mobilizes CD34(+) hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J. Clin. Psychopharmacol. 2010, 30(5):591-595.
56. Löffler S., Löffler-Ensgraber M., Fehsel K., Klimke A. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int. Clin. Psychopharmacol. 2010, 25(2):101-106.
57. Lowe C.M., Grube R.R.A., Scates A.C. Characterization and clinical management of clozapine-induced fever. Ann. Pharmacother. 2007, 41(10):1700-1704.
58. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 1994, 89(5):346-351.
59. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 1997, 26(2-3):221-225.
60. Maggs J.L., Williams D., Pirmohamed M., Park B.K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 1995, 275(3):1463-1475.
61. Manu P., Sarpal D., Muir O., Kane J.M., Correll C.U. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine?. A systematic review of the published literature. Schizophr. Res. 2012, 134(2-3):180-186.
62. Matalka K.Z., Attallah L.J., Qinna N.A., Alhussainy T. Dopamine selectively modulates lipopolysaccharide-induced TNF-alpha, IFN-gamma and IL-10 within mice tissues. Neuro Endocrinol. Lett. 2011, 32(2):176-186.
63. McAllister C.G., Rapaport M.H., Pickar D., Paul S.M. Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch. Gen. Psychiatry 1989, 46(10):956-957.
64. Merrill D.B., Dec G.W., Goff D.C. Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. 2005, 25(1):32-41.
65. Michelsen J.W., Meyer J.M. Cardiovascular effects of antipsychotics. Expert. Rev. Neurother. 2007, 7(7):829-839.
66. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
67. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63(3):257-265.
68. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res. 1997, 71(1):11-17.
69. Mouaffak F., Gaillard R., Burgess E., Zaki H., Olié J.P., Krebs M.O. Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies. Clin. Neuropharmacol. 2009, 32(4):219-223.
70. Munk-Jørgensen P., Nielsen J., Nielsen R.E., Stahl S.M. Last episode psychosis. Acta Psychiatr. Scand. 2009, 119(6):417-418.
71. Nielsen J., Meyer J.M. Risk factors for ileus in patients with schizophrenia. Schizophr. Bull. 2012, 38(3):592-598.
72. Nielsen J., Boysen A. Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophr. Res. 2010, 123(2-3):270-272.
73. Nielsen J., Foldager L., Meyer J.M. Increased use of antibiotics in patients treated with clozapine. Eur. Neuropsychopharmacol. 2009, 19(7):483-486.
74. Nielsen J., Dahm M., Lublin H., Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J. Psychopharmacol. 2010, 24(7):965-971.
75. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010, 35(9):1997-2004.
76. Nielsen J., Damkier P., Lublin H., Taylor D. Optimizing clozapine treatment. Acta Psychiatr. Scand. 2011, 123(6):411-422.
77. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat. Rev. Immunol. 2002, 2(1):37-45.
78. Opgen-Rhein C., Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008, 9(8):1101-1111.
79. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav. Brain Res. 2009, 204(2):313-321.
80. Pereira A., Dean B. Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem. Pharmacol. 2006, 72(6):783-793.
81. Pereira A., McLaren A., Bell W.R., Copolov D., Dean B. Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. Pharmacogenomics J. 2003, 3(4):227-234.
82. Pessina A., Turlizzi E., Bonomi A., Guizzardi F., Cavicchini L., Croera C., Bareggi S. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006, 39(1):20-22.
83. Pollmächer T., Hinze-Selch D., Mullington J., Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch. Gen. Psychiatry 1995, 52(10):877-878.
84. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996, 16(5):403-409.
85. Pontikoglou C., Papadaki H.A. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin 2010, 34(3):291-304.
86. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
87. Pui-yin Chung J., Shiu-yin Chong C., Chung K., Lai-wah Dunn E., Wai-nang Tang O., Chan W.F. The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can. J. Psychiatry 2008, 53(12):857-862.
88. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad. Med. J. 2005, 81(959):545-546.
89. Rettenbacher M.A., Hofer A., Kemmler G., Fleischhacker W.W. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry 2010, 43(2):41-44.
90. Ronaldson K.J., Taylor A.J., Fitzgerald P.B., Topliss D.J., Elsik M., McNeil J.J. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J. Clin. Psychiatry 2010, 71(8):976-981.
91. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., McNeil J.J. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust. N. Z. J. Psychiatry 2011, 45(6):458-465.
92. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., McNeil J.J. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr. Res. 2011, 128(1-3):161-165.
93. Rothermundt M., Arolt V., Bayer T. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 2001, 15(4):319-339.
94. Rudolf S., Peters M., Rothermundt M., Volkert A., Kirchner H. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 2002, 46(4):180-185.
95. Safferman A.Z., Lieberman J.A., Alvir J.M., Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992, 339(8804):1296-1297.
96. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2(5):e141.
97. Schwarz M.J., Chiang S., Müller N., Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 2001, 15(4):340-370.
98. Sheehan N.J. HLA-B27: what's new?. Rheumatology (Oxford) 2010, 49(4):621-631.
99. Simon D., Simon H.U. Eosinophilic disorders. J. Allergy Clin. Immunol. 2007, 119(6):1291-1300.
100. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 45(2):135-141.
101. Song C., Lin A.H., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 2000, 42(2):157-164.
102. Sperner-Unterweger B., Gaggl S., Fleischhacker W.W., Barnas C., Herold M., Geissler D. Effects of clozapine on hematopoiesis and the cytokine system. Biol. Psychiatry 1993, 34(8):536-543.
103. Striano P., Zara F. Epilepsy: HLA alleles linked to carbamazepine hypersensitivity. Nat. Rev. Neurol. 2011, 7(7):365-366.
104. Sugata Y., Okano M., Fujiwara T., Matsumoto R., Hattori H., Yamamoto M., Nishibori M., Nishizaki K. Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology 2007, 121(2):266-275.
105. Suzuki T., Remington G., Mulsant B.H., Uchida H., Rajji T.K., Graff-Guerrero A., Mimura M., Mamo D.C. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012, 197(1-2):1-6.
106. Szuster-Ciesielska A., Słotwińska M., Stachura A., Marmurowska-Michałowska H., Kandefer-Szerszeń M. Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch. Immunol. Ther. Exp. (Warsz.) 2004, 52(1):59-67.
107. Tham J.C., Dickson R.A. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J. Clin. Psychiatry 2002, 63(10):880-884.
108. Tschen A.C., Rieder M.J., Oyewumi L.K., Freeman D.J. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin. Pharmacol. Ther. 1999, 65(5):526-532.
109. Valevski A., Klein T., Gazit E., Meged S., Stein D., Elizur A., Narinsky E.R., Kutzuk D., Weizman A. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 1998, 25(1):11-13.
110. Wehmeier P.M., Heiser P., Remschmidt H. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J. Clin. Psychopharmacol. 2003, 23(1):102-103.
111. Whiskey E., Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007, 21(1):25-35.
112. Williams D.P., Pirmohamed M., Naisbitt D.J., Maggs J.L., Park B.K. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 1997, 283(3):1375-1382.
113. Williams D.P., Pirmohamed M., Naisbitt D.J., Uetrecht J.P., Park B.K. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol. 2000, 58(1):207-216.
114. Woerner M.G., Robinson D.G., Alvir J.M.J., Sheitman B.B., Lieberman J.A., Kane J.M. Clozapine as a first treatment for schizophrenia. Am. J. Psychiatry 2003, 160(8):1514-1516.
115. Zimmermann U., Kraus T., Himmerich H., Schuld A., Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 2003, 37(3):193-220.